

BTK Inhibitors for B-Cell Malignancies:

Clinical Updates for Specialty Pharmacists

WEDNESDAY, MAY 13, 2020

AGENDA

8:00 PM	Session	<p>Kirollos S. Hanna, PharmD, BCPS, BCOP Oncology Pharmacy Manager M Health Fairview Maple Grove, Minnesota Assistant Professor of Pharmacy Mayo Clinic College of Medicine Rochester, Minnesota</p> <p>Anthony Perissinotti, PharmD, BCOP Clinical Pharmacy Specialist – Hematology University of Michigan – Michigan Medicine Ann Arbor, Michigan</p>
9:30 PM	Adjourn	

ACTIVITY OVERVIEW

TARGET AUDIENCE

This continuing education program is directed toward specialty pharmacists, payers, managed care professionals, and pharmacy benefit managers.

ACTIVITY OVERVIEW

B-cell malignancies are a heterogeneous group of cancers impacting B lymphocytes and include most non-Hodgkin lymphomas, such as mantle cell lymphoma, as well as chronic lymphocytic leukemia, and Waldenström macroglobulinemia. With multiple oral BTK inhibitors available, it is necessary for specialty pharmacists to be cognizant of expanding approved indications and the latest clinical and safety data for emerging therapies. Considerations as to patient- and disease-specific factors and nuances within this class of medications are essential to ensure individualized and appropriate management of BTK inhibitors. This session will also review the specialty pharmacist's role on the oncology team in coordinating care and minimizing treatment-related adverse effects to improve adherence and patient outcomes.

EDUCATIONAL OBJECTIVES

Upon completion of this application-based educational activity, participants will be able to:

- Explain the link between the BCR pathway and the role of BTK inhibition in the pathophysiology and treatment of B-cell malignancies
- Determine the recommended treatment for a given B-cell malignancy based on patient- and disease-specific characteristics
- Develop a counseling and monitoring plan for a patient who is newly started on therapy with a BTK inhibitor for the treatment of a B-cell malignancy

HOW TO RECEIVE CREDIT

After attending this session and completing the online evaluation forms, pharmacists may request credit for the activities in which they participated by following the directions below. **All participants must request their credit by July 13, 2020.**

OBTAINING CREDIT INSTRUCTIONS

1. Go to: www.pharmacytimes.org/go/BTK-assembly and log in to your account.
2. Once logged in, click "Proceed".
3. Enter the credit code that will be provided at the end of the session.
4. Complete the activity evaluation and click "Next".
5. Verify your NABP and date of birth, then click "Submit".

Your credit will be uploaded to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net.

NOTE: Participation data will not be uploaded into CPE Monitor if you do not have your NABP (e-profile ID) number and date of birth entered.

ACCREDITATION/DESIGNATION OF CREDIT



Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-073-L01-P. The activity is available for CE credit on May 13, 2020.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from BeiGene, Ltd.

DISCLOSURE POLICY AND RESOLUTION OF CONFLICTS OF INTEREST (COIs)

As a sponsor accredited by the ACPE, it is the policy of *PTCE* to ensure fair balance, independence, objectivity, and scientific rigor in all of its CPE activities. In compliance with ACPE guidelines, *PTCE* requires everyone who is in a position to control the content of a CPE activity to disclose all relevant financial relationships with commercial interests. The ACPE defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, *PTCE* is required by the ACPE to resolve all COIs. *PTCE* has identified and resolved all COIs prior to the start of this activity by using a multistep process.

FACULTY, STAFF, AND PLANNERS' DISCLOSURES

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Anthony Perissinotti, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff

Jim Palatine, RPh, MBA

Maryjo Dixon, RPh

Amy H. Seung, PharmD, BCOP, FHOPA

Brianna Schauer, MBA

Crissy Wilson

Susan Pordon

Brianna Winters

The following individual has relevant financial relationships with commercial interests to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers Bureau	Shareholder	Other
Kirollos S. Hanna, PharmD, BCPS, BCOP		AbbVie, Seattle Genetics	AbbVie, Seattle Genetics	CVS	Ad Boards: AstraZeneca, Incyte, Rigel, Taiho

*Information accurate at time of posting.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

OFF-LABEL DISCLOSURE AND DISCLAIMER

Continuing professional education (CPE) activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of *Pharmacy Times* Continuing Education™ or the company that provided commercial support for this activity.

If you have any questions concerning this broadcast, please call us at 800-597-6372 or email us at ceinfo@pharmacytimes.com.



Kirollos S. Hanna, PharmD, BCPS, BCOP

Oncology Pharmacy Manager
M Health Fairview
Maple Grove, Minnesota
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota

Kirollos S. Hanna, PharmD, BCPS, BCOP, is board certified by the Board of Pharmacy Specialties in oncology pharmacy and pharmacotherapy. He received his doctorate of pharmacy degree from Florida A&M University, completed his general residency at St. Thomas Hospital, Nashville, Tennessee, and his oncology residency at St. Luke's Mountain States Tumor Institute, Boise, Idaho. He is currently an assistant professor of pharmacy at the Mayo Clinic College of Medicine and the oncology pharmacy manager at M Health Fairview, Maple Grove.

Dr Hanna's research interests are focused on outcome measures for patients with rare diseases, B-cell malignancies, and genitourinary cancers. He has published over a dozen peer-reviewed manuscripts in various journals including *Pharmacotherapy*, *AJHP*, *JOPP*, *AJMC*, and *JHOP*. He is also an active member of the Patient-Centered Outcomes Research Institute, Aplastic Anemia and MDS International Foundation, and the American College of Clinical Pharmacy.



Anthony Perissinotti, PharmD, BCOP

Clinical Pharmacy Specialist – Hematology
University of Michigan – Michigan Medicine
Ann Arbor, Michigan

Anthony J. Perissinotti, PharmD, BCOP, is a hematology clinical pharmacist specialist at the University of Michigan–Michigan Medicine, clinical team leader of hematology/oncology, and adjunct clinical assistant professor at the University of Michigan College of Pharmacy in Ann Arbor, Michigan.

Dr Perissinotti obtained his doctor of pharmacy degree from Wayne State University in Detroit, Michigan. He completed his first year of postgraduate residency at the Detroit Medical Center-Harper University Hospital in Detroit, Michigan, and he completed his second year of postgraduate residency training at The University of Texas MD Anderson Cancer Center in Houston. Dr Perissinotti is a board-certified hematology/oncology pharmacist.